Dendreon elects Dennis Fenton to board
This article was originally published in Scrip
Dendreon, a biotech company developing therapeutics to treat cancer, has appointed Dennis Fenton to its board of directors. Dr Fenton has 30 years' experience of the pharmaceutical and biotech industries, including over two decades at Amgen where he most recently served as executive vice-president for operations and compliance officer until 2008. He is currently a board member of Genelux, Napo Pharmaceuticals, Kythera Biopharmaceuticals and XenoPort.